Gilead Sciences | Créances Commerciales



Trade Debtors Changement Date
AbbVie USD 10.92B 553M 2024-12
Agios Pharmaceuticals USD 4.11M 991K 2024-12
ALKERMES USD 394.72M 24.54M 2024-12
Alnylam Pharmaceuticals USD 405.31M 51.46M 2024-12
Amgen USD 6.78B 535M 2024-12
Biogen USD 1.87B 119.3M 2024-12
BioMarin Pharmaceutical USD 660.54M 117.01M 2024-12
Bristol-Myers Squibb USD 14.59B 162M 2025-03
Eli Lilly USD 14B 727.8M 2025-03
Gilead Sciences USD 4.39B 32M 2025-03
GlaxoSmithKline GBP 7.5B 176M 2025-03
Glaxosmithkline GBP 7.32B 542M 2024-12
Incyte USD 823.13M 30.02M 2025-03
J&J USD 16.02B 1.18B 2025-03
Merck USD 11.12B 1.06B 2024-12
Moderna USD 306M 286M 2025-03
Neurocrine Biosciences USD 479.1M 2M 2024-12
Novartis USD 9B 854M 2024-12
Pfizer USD 14.78B 2.92B 2024-12
PTC Therapeutics USD 158.55M 41.42M 2024-12
Regeneron Pharmaceuticals USD 5.56B 650.9M 2025-03
Sanofi 447M 10.18B 2025-03
Sarepta Therapeutics USD 649.73M 133.74M 2024-12
United Therapeutics USD 322M 42.7M 2025-03
Vertex Pharmaceuticals USD 1.61B 141.2M 2024-12



Gilead Sciences Créances Commerciales - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.